1
|
Navarro Aznar V, Campos Bonel A, Escuín Troncho C, Miranda A, Cerrolaza Pascual M, Lanuza Carnicer A, Flamarique Andueza S, Rubio P, Alba Villalba V, Casamayor Franco M, Ibáñez Carreras R. PO-1203 Targeted Intraoperative Radiotherapy Tumour Bed Boost: Our experience. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03167-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
2
|
Camacho Fuentes C, Lanuza Carnicer A, Sánchez Cortés C, Escuin Troncho C, Calderó Torra M, Gascón Ferrer M, Pardo Sus A, Flamarique Andueza S, Campos Bonel A, Sanagustin Piedrafita M, Ibáñez Carreras R. PO-1218 Ultra-hypofractionated whole breast radiotherapy as adyuvant treatment for early breast cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03182-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Samper Ots PM, Vallejo Ocaña C, Martin Martin M, Celada Álvarez FJ, Farga Albiol D, Almendros Blanco P, Hernandez Machancoses A, Rico Oses M, Flamarique Andueza S, Romero Ruperto F, Maria Bueno C, Amaya Escobar E, Guerrero Gómez LL, Couñago F, Del Pino Alcántara M, Ruiz Villar MJ, Monroy Antón JL, Saez Bueno P, Luna Tirado J, Del Mar Puertas M, Bobo A, Diaz de Cerio Martínez I, Gascon Costoso N, Ferrer Albiach C. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentre study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clin Transl Oncol 2021; 24:342-349. [PMID: 34487307 DOI: 10.1007/s12094-021-02697-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Accepted: 08/10/2021] [Indexed: 11/29/2022]
Abstract
PURPOSE/OBJECTIVE(S) Stereotactic body radiotherapy (SBRT) has become the standard of care for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) and for patients who refuse surgery. The aim of this study was to evaluate the effectiveness and safety of primary SBRT in patients with early-stage NSCLC. MATERIALS/METHODS Retrospective multicenter study of 397 patients (416 primary lung tumours) treated with SBRT at 18 centres in Spain. 83.2% were men. The median age was 74.4 years. In 94.4% of cases, the tumour was inoperable. The pathological report was available in 54.6% of cases. SPSS vs 22.0. was used to perform all statistical analyses. RESULTS Complete response was obtained in 53.6% of cases. Significant prognostic factors were standard CT planning (p = 0.014) and 4D cone beam CT (p = 0.000). Acute and chronic toxicity ≥ grade 3 was observed in 1.2% of cases. At a median follow-up of 30 months, local relapse was 9.6%, lymph node relapse 12.8%, distant metastasis 16.6%, and another lung tumour 11.5%. Complete response was the only significant prognostic factor for local relapse (p = 0.012) and distant metastasis (p = 0.001). The local relapse-free survival was 88.7%. The overall survival was 75.7%. The cancer-specific survival was 92.7%. The disease-free survival was 78.7%. CONCLUSION SBRT is an effective and well-tolerated treatment option for patients with early-stage lung cancer who are not suitable for surgery. The most important prognostic factor for local and distant recurrence was complete response, which in our sample depended on the type of CT planning and the IGRT technique.
Collapse
Affiliation(s)
| | | | | | | | - D Farga Albiol
- Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | | | | | - M Rico Oses
- Complejo Hospitalario de Navarra, Navarra, Spain
| | | | | | | | | | | | - F Couñago
- Hospital Universitario Quironsalud y Hospital La Luz Quironsalud, Madrid, Spain
| | | | | | | | - P Saez Bueno
- Hospital Universitario Central de la Defensa "Gómez Ulla", Madrid, Spain
| | - J Luna Tirado
- Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | | | - A Bobo
- Hospital Ruber Internacional, Madrid, Spain
| | | | | | | |
Collapse
|
4
|
García Aguilera C, Méndez Villamón A, Flamarique Andueza S, Villa Gazulla D, Escuín Troncho C, Ponce Ortega J, Puertas Valiño M, Tejedor Gutiérrez M. PO-1171: Low- and Intermediate-Risk Prostate Cancer. Stereotactic Body Radiation Therapy. Our experience. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01189-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Rico M, Flamarique Andueza S, Martín Martínez A, Rodríguez Mendizábal MA, Rosas Gutiérrez L, Martínez López E. How to integrate stereotactic body radiation therapy and hypofractionation in the management of stage III lung cancer in the age of immunotherapy. An Sist Sanit Navar 2020; 43:225-234. [PMID: 32141442 DOI: 10.23938/assn.0855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The constant advances in the field of lung cancer immunotherapy have recently reached the treatment of locally advanced disease with the approval of durvalumab after concurrent chemoradiation. However, radiation therapy continues to be key for controlling the disease at this stage. Over the years, different strategies have been employed to try to optimize outcomes using radiotherapy, with cardiac and pulmonary toxicity as the main limitation on its success. The interest in the use of hypofractionation and stereotactic body radiation therapy for stage III non-small cell lung cancer has increased as knowledge regarding these kinds of treatments has been enhanced. Hypofractionation is a relatively frequent treatment, although the level of evidence that supports it is limited. For its part, stereotactic body radiation therapy has been particularly studied as a boost after chemoradiation, with encouraging results. In both cases, study of how to integrate these tools with chemotherapy and particularly with immunotherapy is essential, as they may have an immunomodulatory role.
Collapse
Affiliation(s)
- M Rico
- Servicio de Oncología Radioterápica. Complejo Hospitalario de Navarra. Pamplona.
| | | | | | | | | | | |
Collapse
|
6
|
Flamarique Andueza S, Rico Osés M, Visus Fernández de Manzanos I, Campo Vargas M, Barrado Los Arcos M, Martín Martínez A, Rodríguez Mendizábal M, Pellejero Pellejero S, Mañeru Cámara F, Martínez López E. EP-1238: Validation of the GPA index in brain metastasis treated with Stereotactic radiosurgery. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31548-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
7
|
Visus Fdez de Manzanos I, Rico Osés M, Flamarique Andueza S, Martin Martínez A, Rodriguez Mendizabal M, Barrado Los Arcos M, Campo Vargas M, Pellejero Pellejero S, Mañeru Cámara F, Manterola Burgaleta A, Martinez Lopez E. EP-1397: A single-centre experience of SBRT and EBRT in Stage I NSCLC patients: local failure and survival. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31706-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|